Insider Selling: Doximity (NYSE:DOCS) Director Sells $34,455.90 in Stock

Doximity, Inc. (NYSE:DOCS) Director Watkin Phoebe Yang sold 1,290 shares of the stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $26.71, for a total value of $34,455.90. Following the completion of the transaction, the director owned 24,744 shares in the company, valued at approximately $660,912.24. The trade was a 4.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Doximity Stock Up 0.1%

DOCS stock opened at $27.95 on Monday. The business has a 50 day moving average price of $25.19 and a 200 day moving average price of $23.25. The stock has a market cap of $4.98 billion, a price-to-earnings ratio of 32.89, a PEG ratio of 21.85 and a beta of 1.22. Doximity, Inc. has a fifty-two week low of $17.15 and a fifty-two week high of $74.33.

Doximity (NYSE:DOCS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.13. Doximity had a return on equity of 18.06% and a net margin of 25.48%.The firm had revenue of $156.62 million during the quarter. During the same period last year, the company earned $0.36 earnings per share. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Doximity, Inc. will post 0.74 EPS for the current year.

Doximity News Roundup

Here are the key news stories impacting Doximity this week:

• Neutral Sentiment: Director Phoebe Yang sold 1,290 Doximity shares for approximately $34,456 at an average price of $26.71, reducing her holdings by about 5%. The sale was executed under a Rule 10b5-1 plan, which generally indicates it was scheduled in advance rather than based on current company information. SEC insider transaction filing
• Negative Sentiment: Several investor-rights law firms publicized a securities class action against Doximity and certain officers. The lawsuit covers investors who purchased DOCS shares between August 8, 2024, and May 13, 2026, and alleges violations of federal securities laws. The allegations have not been proven, but the litigation creates potential legal costs, reputational risk, and uncertainty around the company’s prior disclosures. Kaplan Fox class action announcement
• Negative Sentiment: Law firms including Kaplan Fox, SBS, Robbins LLP, Bronstein Gewirtz & Grossman, Pomerantz, Robbins Geller, and Rosen urged eligible shareholders to seek lead-plaintiff status before the November 16, 2026 deadline. The repeated notices increase visibility of the lawsuit and may weigh on sentiment even though they do not represent new operational or financial developments at Doximity. Robbins LLP class action notice

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Citigroup cut shares of Doximity to an “underperform” rating in a research report on Monday, June 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $41.00 price objective on shares of Doximity in a report on Friday, August 7th. Stifel Nicolaus set a $27.00 target price on Doximity in a research report on Tuesday, September 8th. Wells Fargo & Company downgraded Doximity from an “equal weight” rating to an “underweight” rating and set a $18.00 target price for the company. in a report on Monday, August 10th. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $30.00 target price on shares of Doximity in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $31.95.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of DOCS. Versant Capital Management Inc raised its holdings in shares of Doximity by 1,176.9% in the third quarter. Versant Capital Management Inc now owns 1,826 shares of the company’s stock valued at $52,000 after buying an additional 1,683 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Doximity by 111.0% during the first quarter. Parallel Advisors LLC now owns 2,560 shares of the company’s stock worth $60,000 after buying an additional 1,347 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Doximity by 937.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,833 shares of the company’s stock valued at $66,000 after acquiring an additional 2,560 shares during the period. Leonteq Securities AG increased its position in Doximity by 65.6% in the 1st quarter. Leonteq Securities AG now owns 2,912 shares of the company’s stock valued at $68,000 after acquiring an additional 1,154 shares during the period. Finally, Rockefeller Capital Management L.P. increased its position in Doximity by 264.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 3,014 shares of the company’s stock valued at $133,000 after acquiring an additional 2,187 shares during the period. 87.19% of the stock is owned by hedge funds and other institutional investors.

About Doximity

Doximity, Inc operates a digital platform designed for U.S. medical professionals. Its network enables physicians, nurse practitioners, physician assistants and other healthcare providers to connect with colleagues, exchange clinical information and access professional resources.

The company offers tools for telehealth and care coordination, including video and phone-based communication services, as well as digital faxing and secure messaging capabilities. Doximity also provides medical news and research content tailored to healthcare professionals.

Doximity generates additional business through recruiting and marketing solutions that help healthcare organizations reach clinicians and promote employment opportunities, services and products.